The Pharmaceutical Benefits Advisory Committee (PBAC) has published its agenda for March 2025 and there are 4 generalised Myasthenia Gravis (gMG) treatments for consideration. Two are resubmissions and the other two are new requests for PBS listings. You can see the full agenda here.
The closing date for consumer comments is Wednesday, 29th January 2025. The MAA will be making submissions on your behalf. The MAA is also here to help you make individual submissions by giving you relevant information and guidance, ensuring confident navigation of the process. We will be working hard throughout the Christmas-New Year break with a focus on telling a very strong story, hoping to secure new treatment options that are available as broadly as can be achieved.
We (the Australian Myasthenia community) are offered a unique situation with 4 products being listed. No new products have been offered for Myasthenia for more than 20 years. Gaining access to clinically trialled and targeted products is something worth speaking up for.
Make sure you are subscribed to receive MAA updates as soon as they are published.
To read more about PBAC and the Health Technology Assessment (HTA) process, see recent article here.
